NCT07883980Not yet recruiting
Antiseizure Medications and CBC in Children With Epilepsy
Effect of Antiseizure Medications on Complete Blood Count Parameters Among Egyptian Children With Epilepsy
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This prospective study aims to assess changes in complete blood count parameters among Egyptian children with epilepsy receiving antiseizure medications.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 14 Oct 2026
- Start date
- 20 Oct 2026
- Primary completion date
- 20 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Epilepsy
- NCT number
- NCT07883980
What you commit to
- Study type: Observational
- Planned participants: 80
- From 20 Oct 2026 to the primary completion date, 20 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medications known to affect hematopoiesis
Other illness
- Known hematological disorders
- Known bone marrow disorders
- Known malignancy
- Chronic liver disease
- Chronic kidney disease
- Active infection at the time of assessment
- Known immunodeficiency or systemic inflammatory disease
Other
- Recent blood transfusion
Who the study is looking for
- Children aged 1 to 18 years
- Diagnosed with epilepsy
- Newly diagnosed and not previously received antiseizure medications
- Written informed consent from parent or legal guardian
Age in the registry: 1 year to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.